Antal Rohit Desai

Filings by Antal Rohit Desai span 2 companies, the busiest being PROCEPT BioRobotics Corp and Reata Pharmaceuticals Inc. In total, 101 filings cover trades dated from 17 September 2021 to 9 June 2026.

Both buying and selling appear: 8 purchases worth €18.4M, against 56 sales worth €32.5M. On balance, insiders were net sellers of €14.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 5 share grants and 1 option exercise. In 2026 alone, the filings show 7 purchases and no sales.

A typical purchase (the median) is worth €1.1M. 1 out of 8 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 10 June 2026: a share grant, in PROCEPT BioRobotics Corp. The last insider purchase was made public on 9 March 2026, 229 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.